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Acute megakaryoblastic leukemia (AMKL) is a biologically and cytogenetically heterogeneous subtype of acute myeloid leukemia. AMKL either presents de novo or as therapy-related leukemia after chemotherapy or as a leukemic transformation of chronic myeloproliferative neoplasms. The incidence of AMKL in adult de novo acute myeloid leukemia patients is estimated to be about 1-2%, whereas the incidence in the pediatric population is as high as 5-7%, largely because of its association with Down's syndrome (DS).
1,2 DS-AMKL and non-DS-AMKL have vastly different genetic abnormalities and outcomes. Although patients with DS-AMKL have a favorable prognosis, with a 5-year event-free survival rate between 70 and 80%, children with non-DS-AMKL fare much worse, with a 5-year event-free survival of 22-28%. 2, 3 Similarly, the prognosis of adult AMKL is dismal, with a median survival of B10 months. 1 With respect to the molecular basis for megakaryocytic subtypes of acute myeloid leukemia, DS-AMKL blasts uniformly harbor trisomy 21 and somatic mutations in the X-linked hematopoietic transcription factor, GATA1.
4 Distinct abnormalities, such as t(1;22)(p13;q13), which leads to expression of the OTT-MAL (RBM15-MLK1) fusion protein, t(10;11), t(9;11) or þ 8 are seen in cases of non-DS pediatric AMKL. 4 However, very little is known about the etiology of adult AMKL, as no specific chromosomal rearrangements or genetic mutations have been described, apart from a rare detection of mutations in c-MPL, c-KIT, JAK2, JAK3 or FLT3. [4] [5] [6] Leukemia is caused through a multistep process involving genetic alterations that lead to both a proliferative advantage and a block in terminal differentiation. With respect to DS-AMKL, it is likely that trisomy 21 provides a proliferative advantage to fetal hematopoietic progenitors that harbor GATA1 mutations and that these two alterations are sufficient enough to cause TMD (transient myeloproliferative disorder), a preleukemia that is characterized by an aberrant expansion of megakaryoblasts in the fetal liver and peripheral blood. However, trisomy 21 and GATA1 mutations alone are not sufficient to cause DS-AMKL. Consistent with this model, recent studies have shown that DS-AMKL blasts harbor rare activating mutations in FLT3, JAK2, JAK3 and c-MPL. 5, 6 Despite these new insights, the specific genetic events that cooperate with GATA1 and trisomy 21 in the evolution of AMKL are largely unknown. Moreover, common recurrent genetic abnormalities present in pediatric non-DS AMKL and adult AMKL have not been defined.
To identify novel mutations that are associated with AMKL, we systematically analyzed a cohort of 16 adult non-DS-AMKL (diagnosed by immunophenotype and/or French American British (FAB) criteria) patient samples (Table 1) by nucleotide sequence analysis for mutations in genes that are associated with hematopoietic disorders (FLT3, PTEN, c-MPL, PTPN11 and JAK1) and genes that are implicated in normal megakaryocytic differentiation (NOTCH1, GATA2, ETS2, ERG, MEF2C, GABPA, TEL and FLI1). We assayed all the coding regions of these genes by sequencing with the following exceptions: for NOTCH1, we analyzed sequences that encode the heterodimerization and peptide signal rich in proline, glutamic acid, serine, threonine Table 1 Characteristics of AMKL specimens used in this study Letters to the Editor (PEST) domain; for c-MPL, we sequenced the juxtamembrane domain; for PTEN, we restricted our analysis to the C2 domain; for FLT3, we sequenced the juxtamembrane and tyrosine kinase domains; for JAK1, we sequenced the FERM, JH1 and JH2 domains; and for PTPN11, we analyzed exons 3 and 13, which contain the most prevalent mutations identified to date. Genomic DNA and RNA were extracted from patient samples using a Puregene DNA Purification Kit (Qiagen, Valencia, CA, USA) or Trizol (Invitrogen, Carlsbad, CA, USA), respectively. RNA was reverse transcribed using superscript III (Invitrogen) according to the manufacturer's instructions. Primers were designed to amplify the coding regions of interest; sequences are available on request. Mutational analysis carried out by direct sequencing of PCR products generated from reactions with either cDNA or genomic DNA templates. Given that mutations in essential transcription factors and signaling molecules are frequently associated with hematological malignancies, such as NOTCH1 mutations in T-ALL 7 and JAK2 mutations in myeloproliferative neoplasms, 8 we predicted that mutations in a key regulator of megakaryopoiesis would be associated with AMKL. In our comprehensive sequence analysis of these 13 key regulatory genes (FLT3, PTEN, c-MPL, PTPN11, JAK1, NOTCH1, GATA2, ETS2, ERG, MEF2C, GABPA, TEL and FLI1), we failed to detect novel mutations in any of these genes in AMKL specimens. Two known mutations in FLT3 (D835Y and the ITD) were detected in the non-DS-AMKL cohort, although none were detected in a separate collection of four DS-AMKL and six TMD specimens. Furthermore, although we detected a heterozygous JAK1 mutation in the CMY cell line (leading to R724H substitution), we did not detect JAK1 mutations in any patient specimen. Recently, Hussein et al. 6 reported that 3 of 12 (25%) AMKL patient samples harbored W515L mutations in the c-MPL gene. In contrast to the 25% incidence of c-MPL mutations in AMKL in that study, we failed to detect changes in c-MPL in any of our specimens. Thus, the incidence of c-MPL mutations in AMKL is likely to be far o25%.
To our knowledge, our study is the first comprehensive sequence analysis of key transcription factors that mediate normal megakaryopoiesis. Although we failed to detect novel mutations, we cannot rule out the possibility that insertions, deletions or small chromosomal rearrangements, or alterations in the expression levels of these genes, caused by either mutations in regulatory elements or epigenetic modifications, contribute to the development of AMKL. Future studies using high-throughput approaches to identify novel genetic mutations or epigenetic modifications are required to increase our understanding of the cause of this aggressive and deadly disease.
